MAKING THE PRESS
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Mary Crowley Cancer Research has opened a new Phase I clinical trial for advanced Type 1 Ewing sarcoma, a rare bone cancer affecting children, adolescents, and young adults. The first patient has received the investigational therapy and is currently undergoing a response evaluation. Patients with rapidly recurrent Ewing sarcoma have less than a 10% chance of surviving more than five years, and yet no new treatments have been developed in decades. Read Full Story Here.
Pushing Hope Marine Industry Charity Events raised over $180k for Mary Crowley Cancer Research through a series of charity events August 18-20 in the greater St. Louis area. Read Full Story Here.
The 17th Annual Southwest Airlines Technology Classic Car Show has raised $21k for Mary Crowley Cancer Research. Read Full Story Here.
The physicians, staff, and patients at Mary Crowley Cancer Research are proud to have collaborated with BioVex to help develop and lead the pivotal Phase II trial of the first-of-its-kind cancer-specific, immune-enhancing herpes virus for patients with melanoma, which was just approved by the FDA. Read Full Story Here.
